Biocept Expands Agreement with Plus Therapeutics

September 8, 2023

(24/7 MARKET NEWS) – Biocept, Inc. (BIOC:NASDAQ) announced, this morning, that it signed a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (PSTV:NASDAQ), expanding the two companies’ June 2022 comprehensive laboratory services agreement. Plus is using CNSide, Biocept’s proprietary cerebrospinal fluid (CSF)-based tumor cell capture and enumeration platform, in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or melanomas with suspected leptomeningeal metastases (LM), which is cancer in the membranes that surround the brain and spinal cord.

Biocept is trading at $0.94, up $0.0996 (+11.85%), on 22.24K premarket shares traded.

Its 52-week range is $0.80 to $29.55. Today’s volume is the key to this one, as there’s not much high volume resistance after $1.25 and it could even challenge the gap.

 24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.